PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33328759-11	2020	Circ0001313 competitively bound to miR-452 to upregulate HMGB3, thus promoting NSCLC cell growth.	circ0001313	0-11	high mobility group box 3	Homo sapiens	57-62
33654429-12	2021	Rescue experiments further revealed that miR-876-3p downregulation or HMGB3 upregulation effectively reversed the inhibitory effects of LIN00504 deficiency on breast cancer cells.	lin00504	136-144	high mobility group box 3	Homo sapiens	70-75
31980218-6	2020	RESULTS: The areas under the receiver operating characteristic curve (AUC) for the model with three TAAs panel (GREM1, HMGB3 and PSIP1) was 0.711(95% CI 0.674-0.746) in the training set and 0.858 (95% CI 0.808-0.899) in the validation set, which demonstrated a higher diagnostic capability.	Taa1 protein, mouse	100-104	high mobility group box 3	Homo sapiens	119-124
30623409-9	2019	HMGB3 was a target of miR-513b, and overexpression of HMGB3 could obviously reverse the effect of miR-513 on the proliferation, invasion, migration, and apoptosis of NSCLC cells ( p < 0.05).	mir-513	22-29	high mobility group box 3	Homo sapiens	0-5
31061066-0	2019	Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.	Cisplatin	98-107	high mobility group box 3	Homo sapiens	14-39
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	30-39	high mobility group box 3	Homo sapiens	150-175
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	30-39	high mobility group box 3	Homo sapiens	177-182
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	71-80	high mobility group box 3	Homo sapiens	150-175
31061066-3	2019	In this study, we report that cisplatin sensitivity can be restored in cisplatin-resistant ovarian cancer cells by targeting the chromatin-associated high-mobility group box 3 (HMGB3) protein.	Cisplatin	71-80	high mobility group box 3	Homo sapiens	177-182
31061066-5	2019	Depletion of HMGB3 in cisplatin-sensitive and cisplatin-resistant cells resulted in transcriptional downregulation of the kinases ATR and CHK1, which attenuated the ATR/CHK1/p-CHK1 DNA damage signaling pathway.	Cisplatin	22-31	high mobility group box 3	Homo sapiens	13-18
31061066-5	2019	Depletion of HMGB3 in cisplatin-sensitive and cisplatin-resistant cells resulted in transcriptional downregulation of the kinases ATR and CHK1, which attenuated the ATR/CHK1/p-CHK1 DNA damage signaling pathway.	Cisplatin	46-55	high mobility group box 3	Homo sapiens	13-18
31061066-7	2019	Furthermore, HMGB3 depletion significantly increased apoptosis in cisplatin-resistant A2780/CP70 cells after cisplatin treatment.	Cisplatin	66-75	high mobility group box 3	Homo sapiens	13-18
31061066-7	2019	Furthermore, HMGB3 depletion significantly increased apoptosis in cisplatin-resistant A2780/CP70 cells after cisplatin treatment.	Cisplatin	109-118	high mobility group box 3	Homo sapiens	13-18
31061066-8	2019	Taken together, our results indicate that targeted depletion of HMGB3 attenuates cisplatin resistance in human ovarian cancer cells, increasing tumor cell sensitivity to platinum drugs.	Cisplatin	81-90	high mobility group box 3	Homo sapiens	64-69
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Cisplatin	41-50	high mobility group box 3	Homo sapiens	13-18
30112564-8	2018	Compared with control group, sophoridine group showed decreased HMGB3 protein expression and increased apoptotic rate.	matrine	29-40	high mobility group box 3	Homo sapiens	64-69
30112564-9	2018	These results suggest that sophoridine can inhibit the proliferation of MKN45 cells and promote their apoptosis, which may be related to down-regulation of HMGB3 protein expression.	matrine	27-38	high mobility group box 3	Homo sapiens	156-161
30232806-5	2018	MTT and tumour sphere assays demonstrated that HMGB3 knockdown significantly inhibited cell proliferation.	monooxyethylene trimethylolpropane tristearate	0-3	high mobility group box 3	Homo sapiens	47-52
30166860-4	2018	HMGB3 in human liver cancer tissues were evaluated using bioinformatics databases from GEO, TCGA, and Oncomine.	oncomine	102-110	high mobility group box 3	Homo sapiens	0-5
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Paclitaxel	55-65	high mobility group box 3	Homo sapiens	13-18
27774979-12	2016	Silencing of HMGB3 enhanced sensitive to cisplatin and paclitaxel, and reduced sensitive to oxaliplatin.	Oxaliplatin	92-103	high mobility group box 3	Homo sapiens	13-18
27363334-0	2016	MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.	Tamoxifen	125-134	high mobility group box 3	Homo sapiens	160-165
27007252-7	2016	An SA-binding site mutant of HMGB3 retained its DAMP activity, which was no longer inhibited by SA, consistent with its reduced SA-binding activity.	Salicylic Acid	3-5	high mobility group box 3	Homo sapiens	29-34
27363334-6	2016	In addition, this study also found that silencing of HMGB3 indeed partially phenocopied the effects of miR-27b in reducing tamoxifen resistance and cell invasion and in reversing EMT-like properties.	Tamoxifen	123-132	high mobility group box 3	Homo sapiens	53-58
27363334-7	2016	Therefore, we infer that HMGB3 is a functional target of miR-27b in modulation of tamoxifen resistance and EMT.	Tamoxifen	82-91	high mobility group box 3	Homo sapiens	25-30
27007252-6	2016	Like its human counterpart, HMGB3 binds salicylic acid (SA), which results in inhibition of its DAMP activity.	Salicylic Acid	40-54	high mobility group box 3	Homo sapiens	28-33
27007252-7	2016	An SA-binding site mutant of HMGB3 retained its DAMP activity, which was no longer inhibited by SA, consistent with its reduced SA-binding activity.	Salicylic Acid	96-98	high mobility group box 3	Homo sapiens	29-34
27007252-6	2016	Like its human counterpart, HMGB3 binds salicylic acid (SA), which results in inhibition of its DAMP activity.	Salicylic Acid	56-58	high mobility group box 3	Homo sapiens	28-33
27007252-7	2016	An SA-binding site mutant of HMGB3 retained its DAMP activity, which was no longer inhibited by SA, consistent with its reduced SA-binding activity.	Salicylic Acid	96-98	high mobility group box 3	Homo sapiens	29-34
24993872-9	2014	The mutation, confirmed by 3 orthogonal methods, alters an evolutionarily conserved region of the HMGB3 protein from a negatively charged polyglutamic acid tract to a positively charged arginine-rich motif that is likely to interfere with normal protein function.	Polyglutamic Acid	138-155	high mobility group box 3	Homo sapiens	98-103
24993872-9	2014	The mutation, confirmed by 3 orthogonal methods, alters an evolutionarily conserved region of the HMGB3 protein from a negatively charged polyglutamic acid tract to a positively charged arginine-rich motif that is likely to interfere with normal protein function.	Arginine	186-194	high mobility group box 3	Homo sapiens	98-103
24098490-8	2013	Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3.	Azacitidine	38-43	high mobility group box 3	Homo sapiens	80-85
24098490-8	2013	Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3.	Azacitidine	38-43	high mobility group box 3	Homo sapiens	181-186
24098490-8	2013	Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3.	trichostatin A	44-47	high mobility group box 3	Homo sapiens	80-85
24098490-8	2013	Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3.	trichostatin A	44-47	high mobility group box 3	Homo sapiens	181-186
34973275-0	2022	miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells.	mir-142-3p	0-10	high mobility group box 3	Homo sapiens	59-64
34753396-13	2021	LINC00857 negatively regulates the activity of miR-150-5p, which releases its inhibition on HMGB3 expression.	mir-150-5p	47-57	high mobility group box 3	Homo sapiens	92-97